1.       Oshima Y., Haruki T., Koizumi K., Yonezawa S., Taketani A., Kadowaki M., Saito S.: Practices, Potential, and Perspectives for Detecting Predisease Using Raman Spectroscopy Int J Mol Sci., 24:12170, 2023. IF:5.6.

2.       Okada T., Yamabe K., Jo M., Sakajiri Y., Shibata T., Sawada R., Yamanishi Y.., Kanayama D., Mori H., Mizuguchi M., Obita T., Nabeshima Y., Koizumi K., Toyooka N.: Design and structural optimization of thiadiazole derivatives with potent GLS1 inhibitory activity. Bioorg Med Chem Lett., 93:129438, 2023. IF:2.7.

3.       Jo M., Koizumi K*., Suzuki M., Kanayama D., Watanabe Y., Gouda H., Mori H., Mizuguchi M., Obita T., Nabeshima Y., Toyooka N., Okada T.: Design, synthesis, structure-activity relationship studies, and evaluation of novel GLS1 inhibitors. Bioorg Med Chem Lett., 87:129266, 2022. IF:2.7.

4.       Suzuki Y., Munakata L., Omata D., Koizumi K*., Suzuki R.: Feasibility study of novel nanoparticles derived from Glycyrrhizae radix as vaccine adjuvant for cancer immunotherapy. Immunotherapy,14:1443-1455, 2022. IF:4.0

5.       Haruki T., Yonezawa S., Koizumi K*., Yoshida Y., Watanabe TM., Fujita H.., Oshima Y., Oku M., Taketani A., Yamazaki M., Ichimura T., Kadowaki M., Kitajima I., Saito S.: Application of the Dynamical Network Biomarker Theory to Raman Spectra. Biomolecules, 12:1730, 2022. IF:5.5.

6.       Inujima A., Koizumi K*., Shibahara N.: Immunostimulatory properties of heat-resistant RNA in a decoction of Glycyrrhizae Radix. Biomed Pharmacother, 145:112457, 2022. IF:7.5.

7.       Aihara K., Liu R, Koizumi K., Liu X., Chen L.: Dynamical network biomarkers: Theory and applications. Gene, 808:145997, 2022. IF:3.9.

8.       Fujii T., Shimizu T., Katoh M., Nagamori S., Koizumi K., Fukuoka J., Tabuchi Y., Sawaguchi A., Okumura T., Shibuya K., Fujii T., Takeshima H., Sakai H.: Survival of detached cancer cells is regulated by movement of intracellular Na+,K+-ATPase. iScience. 24:102412, 2021. IF:5.8.

9.       Koizumi K*., Oku M., Hayashi S., Inujima A., Shibahara N., Chen L., Igarashi Y., Tobe K., Saito S., Kadowaki M., Aihara K.: Suppression of Dynamical Network Biomarker Signals at the Predisease State (Mibyou) before Metabolic Syndrome in Mice by a Traditional Japanese Medicine (Kampo Formula) Bofutsushosan. Evid Based Complement Alternat Med., doi: 10.1155/2020/9129134, 2020. IF: 2.2.

10.    Iitsuka H., Koizumi K*., Suzaki M., Otsuka Y., Jo M., Shibahara N.: Immunostimulatory effects of sugar-based nanoparticles in boiling Glycyrrhizae Radix water extracts through TLR4. Biomedical Reports, 12:303-308, 2019.

11.    Koizumi K*., Oku M., Hayashi S., Inujima A., Shibahara N., Chen L., Igarashi Y., Tobe K., Saito S., Kadowaki M., Aihara K.: Identifying pre-disease signals before metabolic syndrome in mice by dynamical network biomarkers. Sci Rep., 24:8767, 2019. IF: 4.6.

12.    Xu J., Koizumi K*., Liu M., Mizuno Y., Suzaki M., Iitsuka H., Inujima A., Fujimoto M., Shibahara N., Shimada Y.: Shikonin induces an anti‑tumor effect on murine mammary cancer via p38‑dependent apoptosis. Oncol Rep. 41:2020-2026, 2019. IF: 3.3.

13.    Prangsaengtong O., Jantaree P., Lirdprapamongkol K., Svasti J., Koizumi K.: Shikonin Suppresses Lymphangiogenesis via NF-κB/HIF-1α Axis Inhibition. Biol Pharm Bull., 41:1659-1666, 2019. IF: 1.8.

14.    Iitsuka H., Koizumi K*., Inujima A., Suzaki M., Mizuno Y., Takeshita Y., Eto T., Otsuka Y., Shimada R., Liu M., Ikeda K., Nakano M., Suzuki R., Maruyama K., Zhou Y., Sakurai H., Shibahara N.: Discovery of a sugar-based nanoparticle universally existing in boiling herbal water extracts and their immunostimulant effect. Biochem Biophys Rep., 16:62-68, 2018.

15.    Igarashi Y., Nawaz A., Kado T., Bilal M., Kuwano T., Yamamoto S., Sasahara M., Jiuxiang X., Inujima A., Koizumi K., Imura J., Shibahara N., Usui I., Fujisaka S., Tobe K.: Partial depletion of CD206-positive M2-like macrophages induces proliferation of beige progenitors and enhances browning after cold stimulation. Sci Rep., 8:14567, 2018. IF: 4.6.

16.    Prangsaengtong O., Jantaree P., Lirdprapamongkol K., Ngiwsara L., Svasti J., Koizumi K.: Aspirin suppresses components of lymphangiogenesis and lymphatic vessel remodeling by inhibiting the NF-κB/VCAM-1 pathway in human lymphatic endothelial cells. Vasc Med., 23:201-211,2018. IF: 2.5.

17.    Takikawa A., Mahmood A., Nawaz A., Kado T., Okabe K., Yamamoto S., Aminuddin A., Senda S., Tsuneyama K., Ikutani M., Watanabe Y., Igarashi Y., Nagai Y., Takatsu K., Koizumi K., Imura J., Goda N, Sasahara M., Matsumoto M., Saeki K., Nakagawa T., Fujisaka S., Usui I, Tobe K.: HIF-1α in Myeloid Cells Promotes Adipose Tissue Remodeling Toward Insulin Resistance. Diabetes., 65:3649-3659, 2016. IF: 8.1.

18.    Matsuo K., Koizumi K.*, Fujita M., Morikawa T., Jo M., Shibahara N., Saiki I., Yoshie O., Nakayama T.: Efficient Use of a Crude Drug/Herb Library Reveals Ephedra Herb As a Specific Antagonist for TH2-Specific Chemokine Receptors CCR3, CCR4, and CCR8. Front Cell Dev Biol., 7:54, 2016. IF: 5.2. (創刊5年が経過しておらず、2019年IFを表記)

19.    Prangsaengtong O., Athikomkulchai S., Xu J., Koizumi K., Inujima A., Shibahara N., Shimada Y., Tadtong S., Awale S.: Chrysin Inhibits Lymphangiogenesis in Vitro. Biol Pharm Bull., 39:466-472, 2016. IF: 1.8.

20.    Takeno N., Inujima A., Shinohara K., Yamada M., Shibahara N., Sakurai H., Saiki I., Koizumi K*.: Immune adjuvant effect of Juzentaihoto, a Japanese traditional herbal medicine, on tumor vaccine therapy in a mouse model. Int J Oncol., 47:2115-2122, 2015. IF: 3.8.

21.    Zhou Y., Yamada N., Tanaka T., Hori T., Yokoyama S., Hayakawa Y., Yano S., Fukuoka J., Koizumi K., Saiki I., Sakurai H.: Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2. Nat Commun. 2015 Jul 9;6:7679. doi: 10.1038/ncomms8679. IF: 13.6.

22.    Wada A., Ito A., Iitsuka H., Tsuneyama K., Miyazono T., Murakami J., Shibahara N., Sakurai H., Saiki I., Nakayama T., Yoshie O., Koizumi K*., Sugiyama T.: Role of Chemokine CX3CL1 in progression of multiple myeloma via CX3CR1 in bone microenvironments. Oncol Rep., 33:2935-2939, 2015. IF: 3.3.

23.    Inujima A., Yamada M., Takeno T., Hoshina A., Oe M., Shinohara K., Shibahara N., Sakurai H., Saiki I., Koizumi K*.: Herbal plant-derived compound, 1,2,3,4,6-penta-O-galloyl-β-d-glucose, increases cross-presentation of antigens to MHC class I molecules by dendritic cells. J. Trad. Med., 2:43-49, 2015.

24.    Refaat A., Aminullah., Zhou Y., Kawanishi M., Tomaru R., Abdelhamed S., Shin MS., Koizumi K., Yokoyama S., Saiki I., Sakurai H.: Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells. Biochem Biophys Res Commun., 20: 856-861, 2015. IF: 2.8.

25.    Kee JY., Inujima A., Andoh T., Tanaka K., Li F., Kuraishi Y., Sakurai H., Shibahara N., Saiki I., Koizumi K*: Inhibitory effect of Moutan Cortex aqueous fraction on mast cell-mediated allergic inflammation. J Nat Med., doi: 10.1007/s11418-014-0880-6, 2015. IF: 1.9.

26.    Kee JY., Ito A., Hojo S., Hashimoto I., Igarashi Y., Tsuneyama K., Tsukada K., Irimura T., Shibahara N., Takasaki I., Inujima A., Nakayama T., Yoshie O., Sakurai H., Saiki I,. Koizumi K*: CXCL16 suppresses liver metastasis of colorectal cancer by promoting TNF-alpha-induced apoptosis by tumor-associated macrophages. BMC Cancer, 14: 949, 2014. IF: 3.4.

27.    Park J.Y., Koizumi K*., Prangsaengtonga O., Inujima A., Igarashi Y., Jo M., Shibahara N.: Shikonin inhibits lymphangiogenesis in vitro via the modulation of cell adhesion. J. Trad. Med., 30: 176-182, 2013.

28.    Saiki I., Koizumi K*., Goto H., Inujima A., Namiki T., Raimura M., Kogure T., Tatsumi T., Inoue H., Sakai S., Oka H., Fujimoto M., Hikiami H., Sakurai H., Shibahara N., Shimada Y., Origasa H.: The long-term effects of a Kampo medicine, Juzentaihoto, on maintenance of antibody titer in elderly people after influenza vaccination. Evid. Based Complement. Alternat. Med., 2013:568074. doi: 10.1155/2013/568074, 2013. IF: 2.2.

29.    Shirouzu T., Watari K., Ono M., Koizumi K., Saiki I., Tanaka C., van Soest R.W., Miyamoto T.: Structure, synthesis, and biological activity of a C-20 bisacetylenic alcohol from a marine sponge Callyspongia sp. J. Nat. Prod., 76(7): 1337-1342, doi: 10.1021/np400297p. 2013. IF: 4.0.

30.    Sato K., Shin M.S., Sakimura A., Zhou Y., Tanaka T., Kawanishi M., Kawasaki Y., Yokoyama S., Koizumi K., Saiki I., Sakurai H.: Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation. Cancer Sci. 104(10): 1315-1322, doi: 10.1111/cas.12225, 2013. IF: 4.8.

31.    Prangsaengtong O., Park J.Y., Inujima A., Igarashi Y., Shibahara N., Koizumi K*.: Enhancement of Lymphangiogenesis In Vitro via the Regulations of HIF-1α Expression and Nuclear Translocation by Deoxyshikonin. Evid. Based Complement. Alternat. Med., 2013; 2013: 148297. doi: 10.1155/2013/148297, 2013. IF: 2.2.

32.    Nakashima A., Yamanaka-Tatematsu M., Fujita N., Koizumi K., Shima T., Yoshida T., Nikaido T., Okamoto A., Yoshimori T., Saito S.: Impaired autophagy by soluble endoglin, under physiological hypoxia in early pregnant period, is involved in poor placentation in preeclampsia.: Impaired autophagy by soluble endoglin, under physiological hypoxia in early pregnant period, is involved in poor placentation in preeclampsia. Autophagy. 9(3):303-316, 2013. IF: 12.0.

33.    Jeong D., Watari K., Shirouzu T., Ono M., Koizumi K., Saiki I., Kim Y.C., Tanaka C., Higuchi R., Miyamoto T.: Studies on lymphangiogenesis inhibitors from Korean and Japanese crude drugs. Biol. Pharm. Bull., 36(1): 152-157, 2013. IF: 2.2.

34.    Kee JY., Arita Y., Shinohara K., Ohashi Y., Sakurai H., Saiki I., Koizumi K*.: Antitumor immune activity by chemokine CX3CL1 in an orthotopic implantation of lung cancer model in vivo. Mol Clin Oncol., 1: 35-40, 2013.

35.    Kee JY., Ito A., Hojo S., Hashimoto I., Igarashi Y., Tsukada K., Irimura T., Shibahara N., Nakayama T., Yoshie O., Sakurai H., Saiki I., Koizumi K*.: Chemokine CXCL16 suppresses liver metastasis of colorectal cancer via augmentation of tumor-infiltrating natural killer T cells in a murine model. Oncol Rep., doi: 10.3892/or.2012.2185, 2012. IF: 3.3.

36.    Kudo Y., Iizuka S., Yoshida M., Nguyen PT., Siriwardena SB., Tsunematsu T., Ohbayashi M., Ando T., Hatakeyama D., Shibata T., Koizumi K., Maeda M., Ishimaru N., Ogawa I., Takata T.: Periostin directly and indirectly promotes tumor lymphangiogenesis of head and neck cancer. PloS One, 7: e44488, 2012.IF: 3.2.

37.    Sanphanya K., Wattanapitayakul SK., Prangsaengtong O., Jo M., Koizumi K., Shibahara N., Priprem A., Fokin VV., Vajragupta O.: Synthesis and evaluation of 1-(substituted)- 3-prop-2-ynylureas as antiangiogenic agents. Bioorg. Med. Chem. Lett., 22: 3001-3005, 2012. IF: 2.4.

38.    3Prangsaengtong O., Senda K., Doki Y., Park JY., Jo M., Sakurai H., Shibahara N., Saiki I., Koizumi K*.: Calpain 1 and -2 play opposite roles in cord formation of lymphatic endothelial cells via eNOS regulation. Hum. Cell, 25: 36-44, 2012. IF: 2.7.

39.    Refaat A., Zhou Y., Suzuki S., Takasaki I., Koizumi K., Yamaoka S., Tabuchi Y., Saiki I., Sakurai H.: Distinct roles of transforming growth factor-beta-activated kinase 1 (TAK1)-c-Rel and interferon regulatory factor 4 (IRF4) pathways in human T cell lymphotropic virus 1-transformed T helper 17 cells producing interleukin-9. J. Biol. Chem., 286: 21092-21099, 2011. IF: 4.2.

40.    Oka H., Goto H., Koizumi K., Nakamura S., Tsuneyama K., Zhou Y., Jo M., Fujimoto T., Sakurai H., Shibahara N, Saiki I., Shimada Y.: Effect of Hachimijiogan against Renal Dysfunction and Involvement of Hypoxia-Inducible Factor-1α in the Remnant Kidney Model. Evid Based Complement Alternat Med. 348686, 2011. IF: 2.2.

41.    Oka H., Goto H., Koizumi K., Nogami T., Watari H., Nakamur S., Zhou Y., Sakurai H., Shibahara N., Saiki I., Shimada Y.: Cinnamaldehyde and paeonol increase HIF-1α activity in proximal tubular epithelial cells under hypoxia. J. Tad. Med., 28: 149-157, 2011.

42.    Prangsaengtong O., Koizumi K*., Senda K., Sakurai H., Saiki I.: eNOS and Hsp90 interaction directly correlates with cord formation in human lymphatic endothelial cells. Lymphat. Res. Biol., 9: 53-59, 2011. IF: 1.6.

43.    Waiwut P., Shin MS., Inujima A., Zhou Y., Koizumi K., Saiki I., Sakurai H.: Gomisin N enhances TNF-α-induced apoptosis via inhibition of the NF-κB and EGFR survival pathways. Mol Cell Biochem., 350:169-75, 2011. IF: 2.7.

44.    Kato S., Koizumi K*., Yamada M., Imujima A., Takeno N., Sakurai H., Nakanishi T., Nakagawa S., Saiki I. A phagocytotic inducer of constituent from herbal plant, pentagalloylglucose (PGG) enhances lipoplex-mediated gene transfection in dendritic cells. Biol. Pharm. Bull., 33:1878-1885, 2010. IF: 2.2.

45.    Lirdprapamongkol K., Sakurai H., Suzuki S., Koizumi K., Prangsaengtong O., Viriyaroj A., Ruchirawat S., Svasti J., Saiki I.: Vanillin enhances TRAIL-induced apoptosis in cancer cells through inhibition of NF-κB activation. in vivo, 24:501-506, 2010. IF: 1.4.

46.    Prangsaengtong O., Koizumi K*., Urano T., Nagata A., Sakurai H., Tohda C., Saiki I.: Methanol extract of polygonati rhizoma enhances the tube formation of rat lymphatic endothelial cells. J. Trad. Med., 27: 59-65, 2010.

47.    Suzuki S., Zhou Y., Refaat A., Takasaki I., Koizumi K., Yamaoka S., Tabuchi Y., Saiki I., Sakurai H.: Human T cell lymphotropic virus 1 manipulates interferon regulatory signals by controlling the TAK1-IRF3 and IRF4 pathways. J. Biol. Chem., 285: 4441-4446, 2010. IF: 4.2.

48.    Koizumi K*., Saitoh, Y., Minami T., Tsuneyama K., Miyahara T., Nakayama T., Sakurai H., Takano Y., Nishimura M., Imai T., Yoshie O., Saiki I.: Role of CX3CL1/fractalkine in osteoclast differentiation and bone resorption. J. Immunol., 183: 7825-7831, 2009. IF: 5.1.

49.    Nishimura M., Shin M.S., Singhirunnusorn P., Suzuki S., Kawanishi M., Koizumi K., Saiki I., Sakurai H.: TAK1-mediated serine/threonine phosphorylation of epidermal growth factor receptor via p38/extracellular signal-regulated kinase: NF-κB-independent survival pathways in tumor necrosis factor alpha signaling. Mol. Cell. Biol., 29: 5529-5539, 2009. IF: 4.0.

50.    Senda K., Koizumi K*., Takeno N., Kato S., Yamada M., Hashimoto I., Sakurai H., Misaki T., Saiki I.: Inducible capillary formation in lymphatic endothelial cells by blocking lipid phosphate phosphatase-3 activity. Lymphat. Res. Biol., 7: 69-74, 2009. IF: 1.9.

51.    Shin M.S., Singhirunnusorn P., Sugishima Y., Nishimura M., Suzuki S., Koizumi K., Saiki I., Sakurai H.: Cross interference with TNF-α-induced TAK1 activation via EGFR-mediated p38 phosphorylation of TAK1-binding protein 1. Biochim. Biophys. Acta, 1793: 1156-1164, 2009. IF: 2.6.

52.    Cho S., Koizumi K*., Takeno N., Kato S., Hashimoto I., Sakurai H., Tsukada K., Saiki I.: Anti-tumor effect of combining CC chemokine 22 (CCL22) and an anti-CD25 antibody on myeloma cells implanted subcutaneously into mice. Mol. Med. Rep., 2: 773-777, 2009. IF: 2.2.

53.    Tsunoda S., Sakurai H., Saitoh Y., Ueno Y., Koizumi K., Saiki I.: Massive T lymphocyte infiltration into the host stroma is essential for FGF-2-promoted growth and metastasis of mammary tumors via neovascular stability. Am. J. Pathol., 174: 671-683, 2009. IF: 4.2.

54.    Yasuda K., Nagakawa O., Akashi T., Fujiuchi Y., Koizumi K., Komiya A., Saiki I., Fuse Hi.: Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. The Prostate, 69:346-351, 2009. IF: 3.3.

55.    Hashimoto I., Koizumi K*., Tatematsu M., Minami T., Cho S., Takeno N., Nakashima A., Sakurai H., Saito S., Tsukada K., Saiki I.: Blocking on the CXCR4/mTOR signaling pathway induces the anti-metastatic properties and type II programmed cell death, autophagic cell death in peritoneal disseminated gastric cancer cells. Eur. J. Cancer, 44: 1022-1029, 2008. IF: 7.1.

56.    Ueno Y., Sakurai H., Tsunoda S., Matsuo M., Choo M.K., Koizumi K., Saiki I.: Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int. J. Cancer, 123: 340-347, 2008. IF: 6.5.

57.    Akashi T., Koizumi K., Tsuneyama K., Saiki I., Takano Y. Fuse H.: Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci., 99: 539-542, 2008. IF: 4.8.

58.    Matsumoto C., Kojima T., Ogawa K., Kamegai S., Oyama T., Shibagaki Y., Kawasaki T., Fujinaga H., Takahashi K., Hikiami H., Goto H., Kiga C., Koizumi K., Sakurai H., Muramoto H., Shimada Y., Yamamoto M., Terasawa K., Takeda S., Saiki I.: A proteomic approach for the diagnosis of "Oketsu" (blood stasis), a pathophysiological concept of Japanese traditional (Kampo) medicine. Evid. Based Complement. Alternat. Med., 5(4): 463-74, 2008. IF: 2.0.

59.    Saitoh Y., Koizumi K*., Sakurai H., Minami T., Saiki I.: RANKL-induced down-regulation of CX3CR1 via PI3K/Akt signaling pathway suppresses Fractalkine/CX3CL1-induced cellular responses in RAW264.7 cells. Biochem. Biophys. Res. Commun., 364: 417-422, 2007. IF: 2.8.

60.    Matsuo M., Yamada S., Koizumi K., Sakurai H., Saiki I.: Tumour-derived fibroblast growth factor-2 exerts lymphangiogenic effects through Akt/mTOR/p70S6kinase pathway in rat lymphatic endothelial cells. Eur. J. Cancer, 43: 1748-1754, 2007. IF: 7.1.

61.    Koizumi K*., Kozawa Y., Ohashi Y., Nakamura E.S., Aozuka Y., Sakurai H., Ichiki K., Doki Y., Misaki T., Saiki I.: CCL21 promotes the migration and adhesion of highly metastatic human non-small cell lung cancer Lu-99 in vitro. Oncol. Rep., 17:1511-1516, 2007. IF: 3.3.

62.    Hojo S., Koizumi K*., Tsuneyama K., Arita Y., Cui Z., Shinohara K., Minami T., Hashimoto I., Nakayama T., Sakurai H., Takano Y., Yoshie O., Tsukada K., Saiki I.: High level expression of chemokine CXCL16 by tumor cells correlated with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res., 67: 4725-4731, 2007. IF: 9.9.

63.    Matsuo M., Sakurai H., Koizumi K., Saiki I.: Curcumin inhibits the formation of capillary-like tubes by rat lymphatic endothelial cells. Cancer Lett., 251: 288-295, 2007. IF: 7.1.

64.    Ogawa K., Kojima T., Matsumoto C., Kamegai S., Oyama T., Shibagaki Y., Kawasaki T., Fujinaga H., Takahashi K., Hikiami H., Goto H., Kiga C., Koizumi K., Sakurai H., Muramoto H., Shimada Y., Yamamoto M., Terasawa K., Takeda S., Saiki I.: Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients. Clin. Biochem., 40: 1113-1121, 2007. IF: 2.5.

65.    Nozaki K., Goto H., Nakagawa T., Hikiami H., Koizumi K., Shibahara N., Shimada Y.: Effects of keishibukuryogan on vascular function in adjuvant-induced arthritis rats. Biol. Pharm. Bull., 30: 1042-1047, 2007. IF: 2.2.

66.    Lee S-J., Sakurai H., Koizumi K., Song G.Y., Bae Y.S., Kim H-M., Kang K-S., Surh Y-J., Saiki I., Kim S.H.: MAPK regulation and caspase activation are required in DMNQ S-52 induced apoptosis in Lewis lung carcinoma cells. Cancer Lett., 233: 57-67, 2006. IF: 7.1.

67.    Yasumoto K., Koizumi K., Kawashima A., Saitoh Y., Arita Y., Shinohara K., Minami T., Nakayama T., Takahashi Y., Yoahie O., Saiki I.: Role of CXCL12 in peritoneal carcinomatosis of gastric cancer. Cancer Res., 66: 2181-2187, 2006. IF: 9.9.

68.    Fukasawa K., Fujii H., Saitoh Y., Koizumi K., Aozuka Y., Sekine K., Yamada M., Saiki I., Nishikawa K.: Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple role in angiogenesis. Cancer Lett., 243: 135-143, 2006. IF: 7.1.

69.    Choo M.K., Kawasaki N., Singhirunnusorn P., Koizumi K., Sato S., Akira S., Saiki I., Sakurai H.: Blockade of transforming growth factor-β-activated kinase 1 activity enhances TRAIL-induced apoptosis through activation of a caspase cascade. Mol. Cancer Ther, 5: 2970-2976, 2006. IF: 5.8.

70.    Saitoh Y., Koizumi K*., Minami T., Sekine K., Sakurai H., Saiki I.: A derivative of aminopeptidase inhibitor (BE15) has a dual inhibitory effect of invasion and motility on tumor and endothelial cells. Biol. Pharm. Bull., 29: 709-712, 2006. IF: 2.2.

71.    FukeY., Shinoda S., Nagata I., Sawaki S., Nomura T., Ryoyama K., Koizumi K., Saiki I.: Preventive effect of oral administration of 6-(methylsulfinyl)hexyl isothiocyanate from wasabi (Wasabia japonica Matsum) against pulmonary metastasis of B16-BL6 mouse melanoma cells. Cancer Detection Prevention, 30: 174-179, 2006. IF: 2.4.

72.    Nakamura E-S., Koizumi K*., Kobayashi M., Saitoh Y., Nakayama T., Sakurai H., Kameda Y., Yoshie O, Saiki I.: RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. Clin. Exp. Metastasis, 23: 9-18, 2006. IF: 3.1.

73.    Ogawa H., Gomi T., Nishizawa M., Hayakawa Y., Endo S., Hayashi K., Ochiai H., Takusagawa F., Pitot H.C., Mori H., Sakurai H., Koizumi K., Saiki I., Oda H., Fujishita T., Miwa T., Maruyama M., Kobayashi M. Enzymatic and biochemical properties of a novel human serine dehydratase isoform. Biochim Biophys Acta, 1764: 961-971, 2006. IF: 2.6. (5年平均IF記載なしのため2019年IFを表記)

74.    Matsuo M., Koizumi K*., Yamada S., Tomi M., Takahashi R., Ueda M., Terasaki T., Obinata M., Hosoya K., Ohtani O., Saiki I.: Establishment of lymphatic and venous endothelial cell limes from tsA58/EGFP transgenic rats. Cell Tissue Res. 326: 749-758, 2006. IF: 3.5.

75.    Mori A., Sakurai H., Choo M-K., Obi R., Koizumi K., Yoshida C., Shimada Y., Saiki I.: Severe pulmonary metastasis in obese and diabetic mice. Int. J. Cancer., 119: 2760-2767, 2006. IF: 6.2.

76.    Akashi T., Koizumi K*., Nagakawa O., Fuse H., Saiki I.: Andorogen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. Oncol. Rep., 16:831-836, 2006. IF: 3.3.

77.    Choo M-K., Sakurai H., Koizumi K., Saiki I.: TAK1-mediated stress signaling pathways are essential for TNF-α-promoted pulmonary metastasis of murine colon cancer cells. Int. J. Cancer, 118: 2758-2764, 2006. IF: 6.5.

78.    Chino A, Sakurai H., Matsuo M., Choo M-K., Koizumi K., Shimada Y., Terasawa K., Saiki I.: Juzentaihoto, a Kampo medicine, enhances IL-12 production by modulating Toll-like receptor 4 signalling pathways in murine peritoneal exudates macrophages. Int. Immunopharmacol., 5: 871-882, 2005. IF: 3.6.

79.    Yoshioka I., Tsuchiya Y., Aozuka Y., Ohnishi Y., Sakurai H., Koizumi K., Tsukada K., Saiki I.: Urinary trypsin inhibitor suppresses surgical stress-facillitated lung metastasis of murine colon cell carcinoma, colon 26-L5 cells. Anticancer Res., 25: 815-820, 2005. IF: 1.9.

80.    Nagakawa O., Junicho A., Akashi T., Koizumi K., Matsuda T., Fuse H., Saiki I.: Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer and prostatic epithelial cells. Oncology Rep., 23: 1217-1221, 2005. IF: 3.3.

81.    Ueno Y., Sakurai H., Matsuo M., Choo M-K., Koizumi K., Saiki I.: Selective inhibition of TNF-α-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib. Br. J. Cancer, 92: 1690-1695, 2005. IF: 6.2.

82.    Kiga C., Nakagawa T., Koizumi K., Sakurai H., Shibagaki Y., Ogawa K., Goto H., Saiki I.: Expression pattern of plasma proteins in spontaneously diabetic rats after oral administration of a Kampo medicine, Hachimi-jio-gan, using SELDI ProteinChip platform. Biol. Pharm. Bull., 28: 1031-1037, 2005. IF: 1.8.

83.    Sakurai H., Singhirunnusorn P., Shimotabira E., Suzuki S., Chino A., Koizumi K., Saiki I.: TAK1-mediated transcriptional activation of CD28-responsive element and AP-1 site within the IL-2 promoter in Jurkat T cells. FEBS Lett., 579: 6641-6646, 2005. IF: 3.4.

84.    Tega E., Kiga C. Chino A., Sakurai H., Koizumi K., Tani T., Saiki I.: A newly devised formulation for self-medication enhances interferon- production and proliferation of splenic lymphocytes. Biol. Pharm. Bull., 28, 1869-1872, 2005. IF: 2.2.

85.    Goto H., Kiga C., Nakagawa T., Koizumi K., Sakurai H., Shibagaki Y. Ogawa K., Shibahara N., Shimada Y., Saiki I.: Effects of two formulations for overcoming oketsu on vascular function and expression patterns of plasma proteins in spontaneously diabetic rats. J. Trad. Med., 22: 237-243, 2005.

86.    Choo M-K., Sakurai H., Koizumi K., Saiki I.: Stimulation of cultured colon 26 cells with TNF-α promotes lung metastasis through the extracellular signal-regulated kinase pathway. Cancer Lett., 230: 47-56, 2005. IF: 7.1.

87.    Nakamura E.S., Koizumi K., Kobayashi M., Saiki I.: Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproreinase inhibitor MMI270. Cancer Sci, 95: 25-31, 2004. IF: 4.8.

88.    Teerawatanasuk N., Nakamura E.S., Koizumi K., Wangmaneerat A., Komatsu K., Saiki I.: Anti-invasive and ant-angiogenic activities of Curucuma sp. extracts. J. Trad. Med., 21: 27-33, 2004.

89.    Suntornsuk L., Koizumi K., Saitoh Y., Nakamura E.S., Kammasud N., Vajaragupta O., Saiki I.: Anti- angiogenic effect of curcumin, curcumin ethylenediamine derivative and curcumin ethylenediamine manganese complex. J. Trad. Med., 21: 94-99, 2004.

90.    Yoshioka Y., Tsutsumi Y., Mukai Y., Shibata H., Okamoto T., Kaneda Y., Tsunoda S., Kamada H., Koizumi K., Yamamoto Y., Mu Y., Kodaira H., Sato-Kamada K., Nakagawa S., Mayumi T.: Effective accumulation of poly(vinylpyrrolidone-co-vinyl laurate) into the spleen. J Biomed. Mater. Res. 70A: 219-223, 2004. IF: 3.5.

91.    Nagakawa O., Akashi T., Hayakawa Y., Junicho A., Koizumi K., Fujiuchi Y., Furuya Y., Matsuda T., Fuse H., Saiki I.: Differential expression of integrin subunits in DU-145/AR prostate cancer cells. Oncology Rep., 12: 837-841, 2004. IF: 3.3.

92.    Aozuka Y., Koizumi K., Saitoh Y., Ueda Y., Sakurai H., Saiki I.: Anti-tumor angiogenesis effect of aminopeptidase inhibitor bestatin against B16-BL6 melanoma orthotopically implanted into syngeneic mice. Cancer Lett., 216: 35-42, 2004. IF: 7.1.

93.    Nakamura E. S., Koizumi K., Yamaura T., Nakajima M., Saiki I.: Anti-tumor angiogenic effect of a matrix metalloproteinase inhibitor MMI-270. Anticancer Res., 23: 411-418, 2003. IF: 1.9.

94.    Nagaoka T., Banskota A.H., Tezuka Y., Harimaya Y., Koizumi K., Saiki I., Kadota S.: Inhibitory effects of caffeic acid phenethyl ester analogues on experimental lung metastasis of murine colon 26-L5 carcinoma cells. Biol. Pharm. Bull., 26: 638-641, 2003. IF: 1.8.

95.    Koizumi K., Tsutsumi Y., Kamada H., Yoshioka Y., Watanabe M., Yamamoto Y., Okamoto T., Mukai Y., Nakagawa S., Tani Y., Mayumi T.: Incorporation of adult organ-derived endothelial cells into tumor blood vessel. Biochem. Biophys. Res. Commun., 306: 219-224, 2003. IF: 2.6.

96.    Koizumi K., Tsutsumi Y.,Yoshioka Y., Watanabe M., Okamoto T., Mukai Y., Nakagawa S., Mayumi T. Anti-angiogenic effects of dimethyl sulfoxide on endothelial cells. Biol. Pharm. Bull., 26: 1295-1298, 2003. IF: 1.8.

97.    Ohashi Y., Tsuchiya Y., Koizumi K., Sakurai H., Saiki I.: Prevention of intrahepatic metastasis by curcumin in an orthotopic implantation model. Oncology, 65, 250-258, 2003. IF: 2.3.

98.    Harimaya Y., Koizumi K., Andoh T., Nojima H., Kuraishi Y., Saiki I.: Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett., 187: 121-127, 2002. IF: 7.1.

99.    Tsunoda S., Kamada H., Yamamoto Y., Ishikawa T., Matsui J., Koizumi K., Kaneda Y., Tsutsumi Y., Ohsugi Y., Hirano T., Mayumi T.: Molecular design of polyvinylpyrrolidone-conjugated interleukin-6 for enhancement of in vivo thrombopoietic activity in mice. J. Control Release., 68:335-341, 2000. IF: 8.6.

100. Wakai Y., Matsui J., Koizumi K., Tsunoda Si., Makimoto H., Ohizumi I., Taniguchi K., Kaiho Si., Saito H., Utoguchi N.,  Tsutsumi  Y., Nakagawa S., Ohsugi Y., Mayumi  T.: Effective Cancer Targeting Using an  Anti-tumor  Tissue Vascular Endothelium-specific  Monoclonal  Antibody (TES-23). Jpn. J. Cancer Res., 91:1319-1325, 2000. IF: 4.8.

101. Tsunoda S., Ishikawa T., Yamamoto Y., Kamada H., Koizumi K., Matsui J., Tsutsumi Y., Hirano T., Mayumi T.: Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent. J. Pharmacol. Exp. Ther., 290:368-372, 1999. IF: 3.6.

102. Tsunoda S., Ohizumi I., Matsui J., Koizumi K., Wakai Y., Makimoto H., Tsutsumi Y., Utoguchi N., Taniguchi K., Saito H., Harada N., Ohsugi Y., Mayumi T.: Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: a novel drug carrier for cancer targeting therapy. Br. J. Cancer., 81:1155-1161, 1999. IF: 6.2.

103. Ohizumi I., Tsunoda S., Taniguchi K., Saito H., Esaki K., Koizumi K., Makimoto H., Wakai Y., Matsui J., Tsutsumi Y., Nakagawa S., Utoguchi N., Ohsugi Y., Mayumi T.: Identification of tumor vascular antigens by monoclonal antibodies prepared from rat-tumor-derived endothelial cells. Int. J. Cancer., 77: 561-566, 1998. IF: 6.5.

104. Makimoto H., Koizumi K., Tsunoda S., Wakai Y., MatsuiI J., Tsutsumi Y., Nakagawa S., Ohizumi I., Taniguchi K., Saito H., Utoguchi N., Ohsugi Y., Mayumi T.: Tumor vascular targeting using a tumor-tissue endothelium-specific monoclonal antibody as an effective strategy for cancer chemotherapy. Biochem. Biophys. Res. Commun., 260: 346-350, 1998. IF: 2.8.

105. Kanzaki Y., Shinoyama Y., Tsukamoto M., Okano M., Suzuki N., Inoue Y., Tanaka T., Koizumi K., Watanabe Y.: Drug Release Characteristic of Ternary Mica/Phosphatidylcoline/Drug Intercalation Compounds. Chem. Pharm. Bull., 46: 1663-1666, 1998. IF: 1.4.

106. Watanabe Y., Endo K., Koizumi K., Matsumoto M.: A New Coppression Tabletting Method Using a Punch Coated with Amorophous Alloys. J. Pharm. Sci. Technol. Jpn., 58: 147-154, 1998.

107. Koizumi K., Watanabe Y., Morita K., Utoguchi N., Matsumoto M.: New method of preparing high-porosity rapidly saliva soluble compressed tablets using mannitol with camphor, a subliming material. Int. J. Pharm., 152: 127-131, 1997. IF: 4.4.

108. Watanabe Y., Utoguchi N., Kimura C., Tai Y., Yamada N., Koizumi K., Kanzaki Y., Matsumoto M.: A new ultraviolet protective agent the intercalation compound of aminpbenzoic acid esters (UV aborber) and synthetic mica (inoraganic layered compound). Chem. Pharm. Bull., 45: 2051-2054, 1997. IF: 1.4.

109. Watanabe Y., Koizumi K., Zama Y., Matsumoto Y., Matsumoto M.: New compressed tablet rapidly disintegrating in saliva in the mouth using crystalline cellulose and a disintegrant. Biol. Pharm. Bull., 18: 1308-1310, 1996. IF: 1.8.


1 | 2020 | 2020 | 令和3年度橋渡し研究 | シーズA | AMED | GLS1阻害剤を基盤としたフレイル治療および予防の開発
2 | 2020 | 2020 | 令和2年度橋渡し研究 | シーズA | AMED | グルタミナーゼ阻害を基盤とした新規抗肥満症薬の開発
3 | 2019 | 2019 | 平成31年度橋渡し研究 | シーズA | AMED | グルタミナーゼ阻害を基盤とした新規抗肥満症薬の開発
4 | 2017 | 2018 | 平成29-30年度橋渡し研究 | シーズA | AMED | 酵素Xを標的とした新規メタボリックシンドローム治療戦略の知財化に向けた基礎研究
5 | 2017 | 2020 | 科学研究費補助金 | 基盤研究B | JSPS | 漢方医薬学と複雑系数理科学の挑戦 ~未病の検出から始まる新たな医療戦略の構築へ~
6 | 2013 | 2013 | 最先端研究開発支援プログラム | FIRST | 内閣府 | 複雑系数理モデル理論による「未病」の検出と漢方薬の薬効機序解明
7 | 2013 | 2014 | 科学研究費補助金 | 挑戦的萌芽研究 | JSPS | 移植するだけでNASHを発症させるNKT細胞の発見、その機能解析と創薬への挑戦
8 | 2012 | 2012 | A-STEP | フィージビリティスタディ | JST | 多発性骨髄腫に対する抗体医薬の開発に向けた検証的臨床研究
9 | 2011 | 2013 | 科学研究費補助金 | 基盤研究C | JSPS | 温度感受性遺伝子導入動物カハール細胞を用いた消化管間質腫瘍の悪性化機序
10 | 2010 | 2012 | 厚生労働科学研究費補助金 | 臨床研究推進研究事業 | 厚生労働省 | 漢方薬によるワクチンアジュバント効果の検討と臨床応用
11 | 2010 | 2012 | 科学研究費補助金 | 基盤研究C | JSPS | リンパ管新生評価系並びにリンパ節転移モデルを用いたリンパ管新生機序解明と治療応用
12 | 2010 | 2012 | 科学研究費補助金 | 基盤研究C | JSPS | ケモカイン機能を利用したがん細胞呼び込み型DDS製剤の開発と腹膜播種治療への応用
13 | 2010 | 2012 | 厚生労働科学研究費補助金 | 創薬基盤推進研究事業 | 厚生労働省 | 粘膜免疫機能を増強する漢方薬の探索とその有効成分の同定
14 | 2007 | 2008 | 科学研究費補助金 | 萌芽研究 | JSPS | 選択的なリンパ管集積性抗体の作製及びがんのリンパ節転移抗体療法の創生
15 | 2006 | 2008 | 科学研究費補助金 | 若手B | JSPS | 温度感受性リンパ管内皮細胞株の樹立及び組織アレイによる腫瘍リンパ管新生分子の検索
16 | 2005 | 2006 | 科学研究費補助金 | 基盤研究C | JSPS | ストレス応答キナーゼTAK1によるがん転移促進作用の分子機構解析
17 | 2004 | 2004 | 科学研究費補助金 | 特定領域研究 | JSPS | がん細胞のリンパ節転移に関与するケモカイン及び受容体の探索と分子標的治療への応用
18 | 2003 | 2005 | 科学研究費補助金 | 若手B | JSPS | 患者血清のプロテオミクス解析による漢方医学診断基準(証)の客観的評価法の構築
19 | 2001 | 2002 | 科学研究費補助金 | 特定領域研究 | JSPS | 同所性移植した肺癌細胞の縦隔リンパ節転移の分子機構の解析とその分子標的治療